CND Life Sciences is pleased to announce the launch of the Syn-One Clinician Network, a directory of some of the hundreds of neurologists who are using the Syn-One Test® to aid in the diagnosis of Parkinson’s disease and other neurological disorders.
Over 2 million people in the US have a synucleinopathy, and 100,000 are diagnosed every year. Many more patients go undiagnosed because there hasn’t been a simple clinical method available
to make a diagnosis.
Be sure to stop by CND Life Sciences’ booth at the upcoming American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting, September 21-24 in Nashville, TN. Learn about the complexities of diagnosing autonomic disorders and small fiber neuropathies and how CND’s Syn-One Test® and Small-Fiber Dx™ can help.
Helping clinicians care for patients and putting patients first are core values at CND Life Sciences, and they require going well beyond offering innovative diagnostic tools such as the Syn-One Test®.
CND Life Sciences’ senior scientific advisors Dr. Christopher Gibbons and Dr. Roy Freeman and two members of CND’s scientific team, Todd Levine, MD, and Bailey Bellaire, presented the results of their study titled “Cutaneous Alpha-Synuclein Detection in Patients with Suspected Synucleinopathies” at the Pan American Parkinson’s Disease and Movement Disorders Congress last month in Miami.
Kendall Swanson started at CND Life Sciences as an intern in the summer before her senior year of college. She was studying psychology, and marketing wasn’t an obvious next step for her. However, CND
was introducing its flagship product to the market during a global pandemic and was looking for good talent to make an instant impact.
A large, population-based study of UK residents demonstrated that a variety of symptoms may be observed in the primary care setting up to a decade before a diagnosis of Parkinson’s disease.
A recent case series report in Movement Disorders examines the potential limitations of dopamine transporter single-photon emission computed tomography (DAT-SPECT) in the diagnosis of Parkinson’s disease, highlighted by cases in which patients with Parkinson’s have scans without evidence of dopaminergic deficit (SWEDDs).
Drs. Pravin Khemani and Michael Elliot from Swedish Neuroscience Institute in Seattle, Washington, published a case study last month in Parkinsonism and Related Disorders that highlights the role of the Syn-One Test in distinguishing overlapping clinical phenotypes of synucleinopathies from non-synucleinopathies.